Agilent Technologies (FRA:AG8) PE Ratio without NRI: 22.64 (As of Jul. 09, 2026) — 13% Below Median


FRA:AG8 Agilent Technologies Inc FRA:AG8
94 GF Score
Price €112.55
GF Value €127.02
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Agilent Technologies PE Ratio without NRI?

Agilent Technologies FRA:AG8 -1.92% 94 PE Ratio without NRI is 22.64 as of Jul. 09, 2026, which is 13% below its 10-year median of 25.99. GuruFocus rates FRA:AG8 with a GF Score™ of 94/100 and a GF Value™ of €127.02 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 98 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 60.2% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-09), Agilent Technologies's share price is €112.55. Agilent Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 was €4.97. Therefore, Agilent Technologies's PE Ratio without NRI for today is 22.64.

During the past 13 years, Agilent Technologies's highest PE Ratio without NRI was 43.62. The lowest was 18.35. And the median was 25.99.

Agilent Technologies's EPS without NRI for the three months ended in Apr. 2026 was €1.27. Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 was €4.97.

As of today (2026-07-09), Agilent Technologies's share price is €112.55. Agilent Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was €4.26. Therefore, Agilent Technologies's PE Ratio (TTM) for today is 26.41.

During the past years, Agilent Technologies's highest PE Ratio (TTM) was 121.98. The lowest was 19.27. And the median was 32.46.

Agilent Technologies's EPS (Diluted) for the three months ended in Apr. 2026 was €1.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was €4.26.

Agilent Technologies's EPS (Basic) for the three months ended in Apr. 2026 was €1.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was €4.27.


Agilent Technologies  (FRA:AG8) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Agilent Technologies PE Ratio without NRI Related Terms


Agilent Technologies PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Agilent Technologies's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agilent Technologies PE Ratio without NRI Chart

Agilent Technologies Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.29 26.50 24.67 29.42 26.18

Agilent Technologies Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.93 21.07 26.18 23.77 19.89

FRA:AG8 vs NTRA, WAT, IDXX: PE Ratio without NRI Comparison

For the Diagnostics & Research subindustry, Agilent Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agilent Technologies PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's PE Ratio without NRI falls into.


FRA:AG8
94GF Score
Agilent Technologies Inc FRA:AG8
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agilent Technologies PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Agilent Technologies's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=112.55/4.971
=22.64

Agilent Technologies's Share Price of today is €112.55.
Agilent Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.97.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 22.64 mean?
Agilent Technologies (FRA:AG8) has a PE Ratio without NRI of 22.64 as of Jul. 09, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Agilent Technologies and its competitors. This is 13% below median its historical median of 25.99. Over the past decade, Agilent Technologies' PE Ratio without NRI has ranged from 18.35 to 43.62. According to the industry distribution chart, Agilent Technologies ranks #39 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 39.8%.
Is Agilent Technologies' PE Ratio without NRI too high?
Agilent Technologies' current PE Ratio without NRI of 22.64 is 13% below median its 10-year median of 25.99. Over the past 10 years, this metric has ranged from a low of 18.35 to a high of 43.62. The Medical Diagnostics & Research industry median PE Ratio without NRI is 30.09. Agilent Technologies' value of 22.64 is 24.7% below this industry median. Based on the distribution chart, Agilent Technologies ranks #39 out of 98 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' PE Ratio without NRI compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #39 out of 98 companies for PE Ratio without NRI. This puts Agilent Technologies in the upper half of its industry. The industry median PE Ratio without NRI is 30.09. Agilent Technologies' value of 22.64 is 24.7% below this benchmark. Historically, Agilent Technologies' own PE Ratio without NRI has ranged from 18.35 to 43.62 over the past decade. While the company's 10-year median is 25.99 vs. the industry median of 30.09, Agilent Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Diagnostics & Research company?
The median PE Ratio without NRI among Medical Diagnostics & Research companies is 30.09, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current PE Ratio without NRI of 22.64 is 24.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Agilent Technologies and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio without NRI is 30.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current PE Ratio without NRI is 22.64, which is 13% below median its own 10-year median of 25.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Modestly Undervalued. The stock's GF Value™ is €127.02, compared to a current price of €112.55 — trading 11.4% below its estimated fair value. The current PE Ratio without NRI is 22.64, which is 13% below median its 10-year median of 25.99 and 24.7% below the Medical Diagnostics & Research industry median of 30.09. Agilent Technologies' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current PE Ratio without NRI is 22.64 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agilent Technologies (FRA:AG8) Overvalued in 2026?

Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued. The current stock price of €112.55 is trading 11.4% below its estimated GF Value™ of €127.02. GuruFocus considers Agilent Technologies to be Modestly Undervalued.

Key valuation signals for FRA:AG8:

  • PE Ratio without NRI: 22.64 (13% below median its 10-year median of 25.99)
  • GF Value™: €127.02 vs. price of €112.55 (11.4% below fair value)
  • GF Score™: 94/100 with 1 warning sign
  • Industry Position: 24.7% below the Medical Diagnostics & Research median (#39 of 98)

No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agilent Technologies Business Description

Address 5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
94GF Score

Get the complete analysis for FRA:AG8

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€112.55
Price
€127.02
GF Value